Please Wait...

John Burns

Main profile

John Burns
Supervisor, IRT Project Management

John has nearly 10 years of experience in the pharmaceutical industry with a focus on IRT project management.  As a BioClinica Senior IRT Project Manager, John leads clinical studies through study closeout, having responsibility for issue management and overall study management.  A member of the BioClinica Trident IRT team since 2013, John brings experience from both the Sponsor and vendor perspectives, including IT management and IRT systems.  John has a Bachelor's degree in Mediated Communication from Rutgers University.

Blogs

Final installment in a three-part series on drug supply shortages in clinical trials with BioClinica's Trident IRT Team.

If you've been following this blog series on drug shortages, you know why it's so important to stay on top of clinical trial drug supply and the potential impact on clinical trials when shortages do occur: subject loss, lowered enrollment, budget escalation, delays and even study discontinuation.

In this blog, we'll see where drug shortages create impacts and what some of the most common root causes are. Coming soon in Part 3 in this series, I'll share some real-life examples of trials where BioClinica was called into rescue mode. So stay tuned and you may pick up some tips to steer clear of drug shortages in your own program.

John Burns, a member of BioClinica's Trident IRT team, was asked to present on drug shortages in clinical trials as part of a panel discussion at DIA. In it, he outlined examples of preventable causes and shared case studies showing what happens when things go awry.  Here is Part 1 in a three-part blog series recapping his discussion.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

[Fun Friday] Now that's using you noodle! Ck this out in @RandDMagazine https://t.co/o5h9O1ScBF
bioclinica (7 hours ago)
FDA, NIH & Industry Advance Templates for Clinical Trial Protocols | RAPS https://t.co/Cqda7fLQZf
bioclinica (Yesterday)
Significant Safety Events Found in a Third of FDA-Approved Drugs, Study Finds | RAPS https://t.co/mAHe42W4or
bioclinica (Yesterday)
FDA Official Highlights Foreign Supply Chain Challenges | RAPS https://t.co/qHDtoRw9MS
bioclinica (Yesterday)
RT @MySCRS: Survey finds 50% of Americans are unaware of #ClinicalTrials, reported by @EdClinical. https://t.co/57x8gtXRT0
bioclinica (Yesterday)
RT @ACROhealth: Recent poll data from @ResearchAmerica, 59% of those polled said their family’s health has been improved by clinical resear…
bioclinica (Yesterday)

Latest Blogs: